However, several clinical studies showed that the development of IGF-1R mAbs (figitumumab and ganitumab) was terminated, even though they exhibited preclinical activity against IGF-1R in some tumors, such as myeloma, prostate cancer, colorectal cancer and pancreatic cancer [22]. The gene discussed is IGF1R; the disease is familial pancreatic carcinoma.